Tags : MabThera/Rituxan

Roche Reports Results of MabThera/Rituxan (rituximab) in P-III PEMPHIX Study

Vartika Singh October 14, 2019

Shots: The P-III PEMPHIX study involves assessing of MabThera/Rituxan vs Mycophenolate Mofetil (MMF) in patients with moderate to severe active PV, requiring 60-120 mg/day oral prednisone (or equivalent) for 52wks. […]readmore

Tags : MabThera/Rituxan

Roche Reports Results of MabThera/Rituxan (rituximab) in P-III PEMPHIX Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : MabThera/Rituxan

Roche Reports Results of MabThera/Rituxan (rituximab) in P-III PEMPHIX Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company